Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

Overview

Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.

Full Title of Study: “Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: September 1, 2020

Detailed Description

Identification of patients with myeloproliferative neoplasms and aquagenic pruritus. Evaluation of the intensity of the aquagenic pruritus. Patients with value >5/10 on the VAS (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood samples will be collected before and after the intakes to study cytokine and neuropeptide levels.

Interventions

  • Drug: Aprepitant 80 mg
    • oral therapy – daily dose – 14 days
  • Drug: Hydroxyzine 25mg
    • oral therapy – daily dose – 14 days
  • Drug: Placebo of Hydroxyzine
    • oral therapy – daily dose – 14 days
  • Drug: Placebo of Aprepitant
    • oral therapy – daily dose – 14 days

Arms, Groups and Cohorts

  • Experimental: studied group
    • Aprepitant 80 mg daily – 14 days Plus placebo of Hydroxyzine – 14 days
  • Active Comparator: comparative group
    • Hydroxyzine 25 mg/d – 14 days Plus placebo of Aprepitant – 14 days

Clinical Trial Outcome Measures

Primary Measures

  • Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale )
    • Time Frame: at 15 days
    • number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms)

Secondary Measures

  • Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale )
    • Time Frame: at 60 days
    • number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms)
  • Cessation of pruritus
    • Time Frame: at 15 days
    • number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms) )
  • Cessation of pruritus
    • Time Frame: at 60 days
    • number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms))
  • Time observed to decreased the VAS to 3/10
    • Time Frame: 01 to 60 days
    • number of days to obtain an intensity of pruritus at 3/10 on the VAS (Visual Analogue Scale )
  • Duration of treatment effectiveness
    • Time Frame: 1 to 60 days
    • number of days the VAS (Visual Analogue Scale ) is below (or equal) 3/10
  • Adverse event occurring during the association therapeutic
    • Time Frame: at 15 days
    • type of adverse event occuring during the treatment period
  • Number of prematurely discontinued anti-pruritic treatment
    • Time Frame: at 15 days
    • Total number of prematurely discontinued treatments for all subjects
  • Complete blood count (normal or abnormal)
    • Time Frame: 1 to 60 days
    • number of patients with hematologic remission : hematocrit <45% with leukocytes <10 giga/l and platelets <400 giga/l
  • Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire
    • Time Frame: at J0 (day of inclusion)
    • Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire
  • Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire
    • Time Frame: at J0 (day of inclusion)
    • Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire
  • Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire
    • Time Frame: at 15 days
    • Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers)questionnaire
  • Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire
    • Time Frame: at 15 days
    • Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire
  • Quality of life through the use of validated questionnaires : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire
    • Time Frame: at 30 days
    • Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire
  • Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire
    • Time Frame: at 30 days
    • Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire
  • Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire
    • Time Frame: at 45 days
    • Evaluation of quality of life by completion of the MPN-SAF(Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire
  • Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire
    • Time Frame: at 45 days
    • Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire
  • Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire
    • Time Frame: at 60 days
    • Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire
  • Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire
    • Time Frame: at 60 days
    • Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire
  • Quantification of the change of plasma concentrations of cytokines and neuropeptides
    • Time Frame: at J0 (day of inclusion)
    • Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)
  • Quantification of the change of plasma concentrations of cytokines and neuropeptides
    • Time Frame: at 15 days
    • Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)
  • Quantification of the change of plasma concentrations of cytokines and neuropeptides
    • Time Frame: at 30 days
    • Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)
  • Quantification of the change of plasma concentrations of cytokines and neuropeptides
    • Time Frame: at 60 days
    • Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)

Participating in This Clinical Trial

Inclusion Criteria

  • Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis) – and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months – and suffering of persistent aquagenic pruritus – and with a pruritus intensity on Analogic Visual Scale >5/10 – patients who gave their written consent for participation in the study Exclusion Criteria:

  • patients with a physical or psychological disability to sign the consent form – patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin – patients already included in another therapeutic protocol – patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo – patients already on anti-anxiety and / or anti-depressant treatment – patients with absolute contraindications to the use of Aprepitant or Hydroxyzine – hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients – lactose intolerance – pregnant or lactating women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Brest
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean-Christophe IANOTTO, MD, PhD, Principal Investigator, Hématologie Clinique-Institut de Cancéro-Hématologie
  • Overall Contact(s)
    • Jean-Christophe IANOTTO, MD, PhD, 02 98 22 37 86, jean-christophe.ianotto@chu-brest.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.